Literature DB >> 23763422

Measles vaccination before the measles-mumps-rubella vaccine.

Jan Hendriks1, Stuart Blume.   

Abstract

At the beginning of the 1960s, it was clear that a vaccine against measles would soon be available. Although measles was (and remains) a killer disease in the developing world, in the United States and Western Europe this was no longer so. Many parents and many medical practitioners considered measles an inevitable stage of a child's development. Debating the desirability of measles immunization, public health experts reasoned differently. In the United States, introduction of the vaccine fit well with Kennedy's and Johnson's administrations' political commitments. European policymakers proceeded cautiously, concerned about the acceptability of existing vaccination programs. In Sweden and the Netherlands, recent experience in controlling polio led researchers to prefer an inactivated virus vaccine. Although in the early 1970s attempts to develop a sufficiently potent inactivated vaccine were abandoned, we have argued that the debates and initiatives of the time during the vaccine's early history merit reflection in today's era of standardization and global markets.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23763422      PMCID: PMC4007870          DOI: 10.2105/AJPH.2012.301075

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  25 in total

1.  MEASLES AND MEASLES VACCINATION.

Authors:  E REES
Journal:  Br Med J       Date:  1964-07-11

2.  VACCINATION AGAINST MEASLES: A STUDY OF CLINICAL REACTIONS AND SEROLOGICAL RESPONSES OF YOUNG CHILDREN. A REPORT TO THE MEDICAL COUNCIL BY THE MEASLES VACCINES COMMITTEE.

Authors:  E NORRBY; R LAGERCRANTZ; S GARD
Journal:  Br Med J       Date:  1965-03-27

3.  Vaccination Against Measles.

Authors: 
Journal:  Br Med J       Date:  1961-11-11

4.  Vaccination of infants in their first year of life with split inactivated measles vaccine incorporated in a diphtheriapertussis-tetanus-polio (inactivated) vaccine (DPTP-M), compared with live measles vaccination.

Authors:  R Brouwer
Journal:  J Biol Stand       Date:  1976

5.  Killed-measles-virus vaccine.

Authors:  V A Fulginiti; C H Kempe
Journal:  Lancet       Date:  1967-08-26       Impact factor: 79.321

6.  Vaccination against measles: clinical trial of live measles vaccine given alone and live vaccine preceded by killed vaccine. Second report to the medical research council by the measles vaccines committee.

Authors: 
Journal:  Br Med J       Date:  1968-05-25

7.  [Measles vaccination].

Authors:  M F Polak
Journal:  Ned Tijdschr Geneeskd       Date:  1968-10-19

8.  Measles vaccination.

Authors: 
Journal:  Lancet       Date:  1966-02-26       Impact factor: 79.321

9.  John F. Enders and measles virus vaccine--a reminiscence.

Authors:  S L Katz
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

10.  Vaccine innovation and adoption: polio vaccines in the UK, the Netherlands and West Germany, 1955-1965.

Authors:  Ulrike Lindner; Stuart S Blume
Journal:  Med Hist       Date:  2006-10       Impact factor: 1.419

View more
  5 in total

Review 1.  Vaccine Design Informed by Virus-Induced Immunity.

Authors:  Rhiannon R Penkert; Jane S Hankins; Neal S Young; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-05-05       Impact factor: 2.257

2.  Nanoscale pathogens treated with nanomaterial-like peptides: a platform technology appropriate for future pandemics.

Authors:  Alaa F Nahhas; Alrayan F Nahhas; Thomas J Webster
Journal:  Nanomedicine (Lond)       Date:  2021-05-14       Impact factor: 5.307

Review 3.  Vaccine hesitancy : Report of a student study group.

Authors:  Lisa Weitz; Luise Bellach; Alicia Faltum; Angelika Berger; Wolfgang Maurer
Journal:  Wien Klin Wochenschr       Date:  2020-04-22       Impact factor: 1.704

4.  Measles Elimination: Identifying Susceptible Sub-Populations to Tailor Immunization Strategies.

Authors:  Peter Kreidl; David Ammerer; Reinhard Würzner; Anita Luckner Hornischer; Dorothee von Laer; Wegene Borena
Journal:  Viruses       Date:  2019-08-20       Impact factor: 5.048

Review 5.  SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates.

Authors:  Nikolaos C Kyriakidis; Andrés López-Cortés; Eduardo Vásconez González; Alejandra Barreto Grimaldos; Esteban Ortiz Prado
Journal:  NPJ Vaccines       Date:  2021-02-22       Impact factor: 7.344

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.